BridgeBio Pharma

PALO ALTO, Calif., July 14, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a…
Read More...

– Project ‘NADER’ is intended to span multiple phases, starting from mapping rare diseases in the UAE and wider region…
Read More...

<!-- Name:DistributionId Value:8790244 --> <!--…
Read More...

- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects…
Read More...

Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i,…
Read More...

- Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic…
Read More...

– BBP-711 led to near complete inhibition of glycolate oxidase throughout the dosing period and greater than 10-fold…
Read More...

- BBP-671 detected in healthy volunteer plasma and cerebrospinal fluid (CSF), suggesting that BBP-671 is entering the…
Read More...

-Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in…
Read More...

- NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or…
Read More...